Production (Stage)
Alto Neuroscience, Inc.
ANRO
$3.03
$0.103.41%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -15.17M | -15.20M | -16.78M | -16.03M | -13.42M |
| Total Depreciation and Amortization | 171.00K | 170.00K | 122.00K | 113.00K | 97.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.10M | 1.91M | 2.15M | 2.79M | 2.59M |
| Change in Net Operating Assets | -4.66M | 99.00K | 2.79M | 1.43M | -255.00K |
| Cash from Operations | -16.56M | -13.02M | -11.73M | -11.69M | -10.98M |
| Capital Expenditure | -24.00K | -506.00K | -1.01M | -340.00K | -224.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -24.00K | -506.00K | -1.01M | -340.00K | -224.00K |
| Total Debt Issued | 19.69M | 1.25M | -- | -- | -- |
| Total Debt Repaid | -10.21M | -- | -- | -- | -- |
| Issuance of Common Stock | 198.00K | 49.00K | 67.00K | 61.00K | 137.59M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -546.00K | -1.25M | 1.25M | -295.00K | -3.03M |
| Cash from Financing | 9.13M | 49.00K | 1.32M | -234.00K | 134.56M |
| Foreign Exchange rate Adjustments | -22.00K | 6.00K | -7.00K | -5.00K | -5.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -7.48M | -13.47M | -11.42M | -12.27M | 123.35M |